The U.S. Food and Drug Administration authorized a third COVID shot for immunocompromised patients. The Pfizer and Moderna vaccines have not been fully approved, and neither company has completed late-stage clinical trials proving a third dose will work.
The U.S. Food and Drug Administration (FDA) Thursday authorized a third dose of Pfizer-BioNTech and Moderna COVID vaccines for people with compromised immune systems.
Neither vaccine has yet received full FDA approval, and neither has completed late-stage clinical trials proving a third dose will boost immunity or work against COVID variants.
The amended Emergency Use Authorization allows people who have had an organ transplant, or those with a similar level of weakened immune system, to get an extra COVID vaccine dose.
The FDA did not approve a Johnson & Johnson booster, citing insufficient data.
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices today voted unanimously to recommend the CDC follow the FDA’s guidance by also approving the third shots for immunocompromised patients.
Thursday’s decision by the FDA “allows doctors to boost immunity in certain immunocompromised individuals who need extra protection from COVID-19,” Dr. Janet Woodcock, FDA acting commissioner, tweeted Thursday.